5.0% Lifitegrast滴眼液治疗中重度干眼症疗效的事后分析
该事后分析基于两项为期12周的双盲随机对照试验(OPUS-2和OPUS-3),纳入1429例干眼症患者,按基线角膜染色评分和眼干评分分层。
要点
- Lifitegrast在中重度干眼症亚组中显示出更高的临床应答 odds。
- 整体人群中,Lifitegrast的应答率和复合应答率均优于安慰剂。
- 临床有意义改善定义为症状改善≥30%且ICSS改善≥1分或TCSS改善≥3分。
核心结论
- Lifitegrast滴眼液5.0%可能对中重度干眼症体征和症状患者产生治疗应答。
研究设计与样本
- 事后应答分析,使用两项3期、12周、前瞻性、双盲、多中心、安慰剂对照、随机平行臂临床试验(OPUS-2和OPUS-3)的数据。
- 共分析1429例参与者(安慰剂组716例,Lifitegrast组713例;女性1087例,占76.1%;平均年龄58.7岁,SD 14.3)。
- 按基线ICSS(≤1.5 vs >1.5)和EDS(<60 vs ≥60)分层为4个亚组。
关键数值与推荐
- 临床有意义改善定义为症状(EDS或整体VAS)改善至少30%,且ICSS改善至少1分或TCSS改善至少3分。
- 复合应答终点对包括:EDS降低至少30%且ICSS改善至少1分;EDS降低至少30%且TCSS改善至少3分;整体VAS改善至少30%且ICSS改善至少1分;整体VAS改善至少30%且TCSS改善至少3分。
临床怎么用
- 对于中重度干眼症患者(ICSS>1.5且EDS≥60),Lifitegrast可能带来临床有意义的体征和症状改善。
局限性
- 本研究为事后分析,结果需谨慎解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: An investigation of the treatment effect of lifitegrast ophthalmic solution, 5.0%, in different subgroups by severity of dry eye disease (DED) seems warranted. OBJECTIVE: To explore the heterogeneity across different subgroups of DED and identify which participants were most likely to achieve clinically meaningful benefit with lifitegrast treatment. DESIGN, SETTING, AND PARTICIPANTS: This post hoc responder analysis was performed using the data from the phase 3 OPUS-2 and OPUS-3 studies, which were 12-week, prospective, double-masked, multicenter, placebo-controlled, randomized, parallel-arm clinical trials that previously demonstrated the efficacy of lifitegrast in DED. Pooled data were stratified into 4 subgroups based on severity of inferior corneal staining score (ICSS; ≤1.5 vs >1.5) and eye dryness score (EDS; <60 or ≥60) at baseline. Data were collected from December 7, 2012, to October 5, 2015, and post hoc analysis was performed from April 14, 2020, to July 30, 2021. INTERVENTIONS: Lifitegrast or placebo twice daily for 84 days. MAIN OUTCOMES AND MEASURES: Proportion of participants with (1) a clinically meaningful improvement in signs (ICSS or total corneal staining score [TCSS]) and symptoms (EDS or global visual analog scale [VAS]) and (2) a composite response for a given sign and symptom end point pair at day 84 were measured. Clinically meaningful improvement was defined as at least 30% improvement in symptoms (EDS or global VAS) and either at least a 1-point improvement in ICSS or at least a 3-point improvement in TCSS. For the composite responder analysis, the end point pairs were defined as at least a 30% reduction in EDS and at least a 1-point improvement in ICSS; at least a 30% reduction in EDS and at least a 3-point improvement in TCSS; at least a 30% improvement in global VAS and at least a 1-point improvement in ICSS; and at least a 30% improvement in global VAS and at least a 3-point improvement in TCSS. RESULTS: In total, 1429 participants (716 in the placebo group and 713 in the lifitegrast group) were analyzed (1087 women [76.1%]; mean [SD] age, 58.7 [14.3] years). For the overall pooled population, responder and composite responder rates favored lifitegrast vs placebo (odds ratio range, 1.29 [95% CI, 1.05-1.59] to 2.10 [95% CI, 1.68-2.61]; P ≤ .02). In the composite analysis, the subgroup with ICSS of greater than 1.5 and EDS of at least 60 at baseline (ie, moderate to severe DED) demonstrated a 1.70- to 2.11-fold higher odds of achieving clinically meaningful improvement with lifitegrast across all sign and symptom end point pairs (P ≤ .001). CONCLUSIONS AND RELEVANCE: These post hoc findings suggest that lifitegrast ophthalmic solution, 5.0%, treatment may be associated with a response in participants with moderate to severe signs and symptoms of DED. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02284516.
引用
- Holland EJ, Jackson MA, Donnenfeld E, et al. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials. JAMA Ophthalmol. 2021. PMID: 34617974. doi:10.1001/jamaophthalmol.2021.3943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。